Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization

The Oregon Psilocybin Services Act created the first state-regulated framework for legal psilocybin services in the United States, with supervised administration in licensed centres rather than medical treatment in the traditional sense. The introduction explains that interest in psilocybin has grown because of emerging clinical and naturalistic evidence for possible benefits in conditions such as depression, substance use disorders, and end-of-life anxiety. At the same time, the authors note that little was known about who was using the Oregon system, why they were using it, and how safe it was during routine statewide implementation. Yu and colleagues therefore set out to characterise utilisation, client demographics, motivations for use, and acute behavioural and medical adverse events during the first full calendar year of regulated psilocybin services in Oregon. They frame the work as a policy-relevant monitoring exercise, intended to inform safety surveillance, equity assessment, and broader discussions about regulated psychedelic access outside clinical trials.

The authors conducted a descriptive analysis of publicly available, aggregate-level data from the Oregon Psilocybin Services dashboard archives covering the full 2025 calendar year, from 1 January to 31 December. The study used quarterly dashboard CSV files, the 303 Client Data Form, and Oregon Psilocybin Services fact sheets. Because the analysis relied only on public, de-identified aggregate data, the University of Arkansas for Medical Sciences Institutional Review Board classified it as Not Human Subjects Research. The dataset contained 386 variables and captured service volume, denials of service, adverse events, and client demographics. Data were aggregated at centre level, so the researchers could not track individual clients across quarters or determine whether some clients participated more than once. Counts for clients served therefore represent the sum reported by centres within each reporting period, not unique persons across the year. Safety events were classified by the state into adverse behavioural, severe behavioural, adverse medical, and severe medical reactions. An adverse reaction was defined as one requiring emergency services or contact with a medical provider during the session, while a severe adverse reaction required hospital transport. Demographic variables included age, gender identity, sexual orientation, and race/ethnicity. Residency was grouped as Oregon, other parts of the United States, or outside the United States to estimate service tourism, and reasons for use were captured through a multi-select checklist covering wellness, mental health diagnoses, trauma, and spiritual growth. Analyses were performed on statewide aggregates. Suppressed values coded as -99 were excluded from percentage calculations, so some results are minimum estimates. Proportions for reasons for use were calculated using the number of clients served in each quarter as the denominator. For safety outcomes, the authors calculated 95% confidence intervals for behavioural and medical adverse event rates per 1,000 sessions using the Wilson score method, which is useful for small event counts.

In 2025, 5,935 clients were served across 5,375 administration sessions, including 747 group administrations with two or more psilocybin recipients in the same session. Utilisation peaked in the second quarter, with 1,758 clients and 1,635 sessions, and then stabilised in the second half of the year, with 1,310 clients in Q3 and 1,358 in Q4. Denial rates declined from 8.0% in Q1 to 1.3% in Q3, then rose slightly to 4.3% in Q4. The main reasons for denial were ineligibility or requests that did not match the centre’s business model. Acute intoxication was not reported as a reason for denial in any quarter. Acute adverse events were uncommon. The annual behavioural adverse event rate was 2.42 per 1,000 sessions, based on 13 events, and the annual medical adverse event rate was 2.79 per 1,000 sessions, based on 15 events. Quarterly rates were highest in Q3 for both categories and lowest in Q4. Severe reactions requiring hospital transport were rare, with five severe behavioural and two severe medical reactions reported across the year, seven in total. The client population was concentrated in midlife adults. The 35-49 age group consistently formed the largest segment, accounting for about 40% of all clients. Participation in most age bands peaked in Q2, especially among people aged 30-34 and 35-39. Clients aged 65 and older made up less than 15% of the annual total. Women consistently represented a majority of participants, ranging from 54.5% to 59.0%. Reporting of gender identity improved over the year, with missing or no-answer responses falling substantially by Q4. LGBTQ+ representation was substantial, peaking at 32.4% in Q1 and then stabilising at roughly one-quarter of participants for the rest of the year. Racial and ethnic diversity was limited: White and European-descended groups made up 84.1% to 91.5% of the population across quarters. Hispanic/Latino participation declined from 9.8% in Q1 to 5.6% in Q4, while African American participation remained around 1.9% to 2.4%. The most common reasons for seeking services were general health and wellness (30.6% annually), change of perspective (27.7%), and expanded consciousness (27.0%). Mental health-related reasons were also common and fairly stable across the year: anxiety was reported by 23.8% of clients, depression by 22.0%, and post-traumatic stress disorder by 13.1%. Service tourism was prominent. Overall, 32.6% of clients lived outside Oregon, including 29.5% from other US states and about 3% from outside the United States. The proportion of out-of-state clients peaked in Q3 at 38.5%. International participation was highest in Q2. The average psilocybin dose stayed broadly similar across quarters, ranging from 24.10 mg to 24.86 mg, although the authors state that session-level variability and dose ranges were not available in the aggregate data.

The authors interpret the findings as showing that Oregon’s first year of regulated psilocybin services was marked by stable utilisation and very low rates of serious acute harm. They argue that the rarity of adverse events, especially events requiring hospital transport, suggests that supervised psilocybin administration can be implemented safely in a regulated, non-medical setting for carefully selected participants. However, they stress that this conclusion must be cautious because the data capture only acutely observable events, and the distinction between behavioural and medical events in aggregate reporting is not especially precise. Yu and colleagues place the results alongside earlier clinical and safety reports, noting that the low frequency of serious events is consistent with previous trial data and safety communications. They also highlight that the programme appears to serve both wellness-oriented users and people seeking relief from mental health distress, even though no formal diagnosis is required. In their view, this suggests that some clients may be using the service as a functional alternative pathway for therapeutic aims outside conventional healthcare. The authors emphasise several equity concerns. They suggest that the midlife age profile, the predominance of women, and the large share of out-of-state clients point to a model that is likely easier to access for people with greater financial resources. They describe the 32.6% service tourism rate as evidence of a persistent “wealth gap” in access. They also note that the programme reached notable proportions of LGBTQ+ and gender-diverse clients, which they view as encouraging, although they do not conclude whether this reflects community demand, culturally competent facilitation, or both. By contrast, racial and ethnic diversity lagged well behind Oregon’s population profile, and the authors interpret this as reflecting structural barriers, including high out-of-pocket costs and the limits of equity training and fee adjustments alone. The main limitations they acknowledge are the aggregate and cross-sectional nature of the data, which prevents individual-level follow-up, identification of repeat clients, assessment of long-term safety, or evaluation of clinical benefit. They also note missing demographic data, voluntary reporting, and privacy-related suppression of small cells, all of which weaken equity inference. Because OPS does not collect validated outcome measures, the authors say the data cannot show whether services improve symptoms or functioning. They further caution that safety events may be underreported or misclassified in a non-medical framework, especially because licencees may not have the clinical credentials typically used to judge adverse events in research or practice. The authors say the programme provides a strong real-world foundation for future policy and research, but they argue that longitudinal outcomes research, more precise safety reporting, and work on affordability and community-specific outreach are needed. They also suggest that future collaboration with healthcare systems may be important to support continuity of care for clients seeking help for mental health concerns.

The authors conclude that Oregon’s psilocybin services programme is a pioneering regulated model that appears to have delivered a stable first year of utilisation with consistently low rates of acute adverse behavioural and medical events. They state that the programme has reached important numbers of LGBTQ+ and gender-diverse clients, but that racial and ethnic diversity remains limited and that service tourism indicates ongoing geographic and socioeconomic barriers. They present the programme as serving both wellness and mental health-related needs, while noting that better affordability, more precise safety monitoring, and longitudinal outcome research are still needed to understand its longer-term public health impact.